Inactive Instrument

Decibel Therapeutics, Inc. Stock price




Biotechnology & Medical Research

on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Dynamic Chart
Managers TitleAgeSince
Director of Finance/CFO 60 23-09-21
Director/Board Member - 23-09-21
Treasurer - 23-09-21
Members of the board TitleAgeSince
Director/Board Member - 23-09-21
More insiders
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company's pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
More about the company
  1. Stock
  2. Equities
  3. Stock Decibel Therapeutics, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.